ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2013
What the infectious disease physician needs to know about pegylated interferon and ribavirin.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- In vitro fertilization for women infected by hepatitis C virus: a matched case-control study and a systematic literature review.Journal of assisted reproduction and genetics · 2017Pooled it
- Hepatitis C virus-associated cardiomyopathy: A review of pathogenesis.World journal of virology · 2025Article
- Host-directed approaches in the pursuit of a cure for HIV.Antiviral research · 2025Review
- Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.Annals of hematology · 2021Review
- The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015.BMC infectious diseases · 2017Article
- KIR2DS2 as predictor of thrombocytopenia secondary to pegylated interferon-alpha therapy.The pharmacogenomics journal · 2017Article
- Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials.Therapeutics and clinical risk management · 2017Review
- Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection.Liver international : official journal of the International Association for the Study of the Liver · 2017Review
- Middle East Respiratory Syndrome Virus Pathogenesis.Seminars in respiratory and critical care medicine · 2016Review
- Antiviral Treatment Guidelines for Middle East Respiratory Syndrome.Infection & chemotherapy · 2015Review
- Inosine triphosphatase allele frequency and association with ribavirin-induced anaemia in Brazilian patients receiving antiviral therapy for chronic hepatitis C.Memorias do Instituto Oswaldo Cruz · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that do not require interferon or even ribavirin. However, pegylated interferon and ribavirin will remain the backbone of hepatitis C therapy for the time being. This review summarizes the pharmacokinetics of peginterferon and ribavirin with a particular emphasis on their side-effect profile and management. Finally, the continued role of peginterferon and ribavirin in future therapies will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.